Echinomycin - OncoImmune

Drug Profile

Echinomycin - OncoImmune

Latest Information Update: 30 Mar 2016

Price : $50

At a glance

  • Originator OncoImmune
  • Class Cytostatic antibiotics
  • Mechanism of Action DNA synthesis inhibitors; Hypoxia-inducible factor-1 alpha inhibitors; RNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Acute myeloid leukaemia

Most Recent Events

  • 29 Mar 2016 Preclinical trials in Acute myeloid leukaemia in USA (unspecified route) prior to March 2016 (OncoImmune pipeline, March 2016)
  • 29 Mar 2016 Pharmacodynamics data from a preclinical trials in Acute myeloid leukaemia and Lymphoma released by Oncoimmune (Oncoimmune website, March 2016)
  • 21 May 2015 Echinomycin receives Orphan Drug status for Acute myeloid leukaemia in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top